These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 4035227)

  • 1. [Effect of sulodexide on hemorheological parameters in a group of patients with peripheral arteriosclerotic vascular disease].
    Calabrò A; Rossi A; Baiocchi MR; Coscetti G; Fellin R; Crepaldi G
    Ric Clin Lab; 1985; 15 Suppl 1():455-63. PubMed ID: 4035227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary results of sulodexide treatment in patients with peripheral arteriosclerosis and hyperlipidemia. A multicentre trial.
    Crepaldi G; Fellin R; Calabrò A; Baiocchi MR; Rossi A; Lenzi S; Descovich GC; Delmonte G; Gaddi A; Ventura A
    Monogr Atheroscler; 1986; 14():215-21. PubMed ID: 3526129
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of 3-glucosaminoglycan sulfate on hemorheologic parameters in hyperlipidemic peripheral vascular disease (PVD) patients: a preliminary double-blind crossover study.
    Ciuffetti G; Mercuri M; Susta A; Lupattelli G; Pasqualini L; Lombardini R; Mannarino E
    Angiology; 1989 Apr; 40(4 Pt 1):255-9. PubMed ID: 2705632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of anti-thrombophilic properties of heparan sulfate in venous vascular pathology. A controlled clinical study versus active reference].
    Ganassin L; Sogaro F; Galeazzi E
    Minerva Cardioangiol; 1991; 39(7-8):275-83. PubMed ID: 1780078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopidogrel: hemorheological effects in subjects with subclinical atherosclerosis.
    Ciuffetti G; Lombardini R; Pirro M; Lupattelli G; Mannarino E
    Clin Hemorheol Microcirc; 2001; 25(1):31-9. PubMed ID: 11790868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experience with sulodexide (Vessel Due F) in diabetics with ischemic disease of the lower extremities].
    Utratová J; Mayer J; Elbl L; Vorlícek J; Prásek J
    Vnitr Lek; 1993 Jun; 39(6):575-80. PubMed ID: 8212613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemorheological mechanisms in Alzheimer's disease.
    Chang CY; Liang HJ; Chow SY; Chen SM; Liu DZ
    Microcirculation; 2007 Aug; 14(6):627-34. PubMed ID: 17710633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hemorheological aspects in relation to age and to the presence of arteriosclerotic disease].
    Neirotti M; Molaschi M; Pernigotti L; Milla A; Fabris F
    Ric Clin Lab; 1989; 19 Suppl 1():69-74. PubMed ID: 2629090
    [No Abstract]   [Full Text] [Related]  

  • 9. [Sulodexide treatment approach in patients with atherosclerotic vascular disease with various localizations].
    Capone-Braga M; Tellini L; Boncompagni L; Bettoni M; Burali A; Bensi A
    Clin Ter; 1987 Jan; 120(1):25-31. PubMed ID: 2973852
    [No Abstract]   [Full Text] [Related]  

  • 10. [Significance of hemorheological parameters within the framework of chronic brain disease].
    Pernigotti L; Neirotti M; Cappa G; Musso M; Fabris F
    Ric Clin Lab; 1985; 15 Suppl 1():307-12. PubMed ID: 4035220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of sulodexide on blood viscosity in patients with peripheral vascular disease.
    Castelluccio A; Bologna E
    Curr Med Res Opin; 1991; 12(5):325-31. PubMed ID: 2004545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of penicillin G-induced epileptic seizures on hemorheological parameters in rats.
    Adigüzel E; Küçükatay V; Erken G; Yonguç N; Bor-Küçükatay M
    Life Sci; 2006 Nov; 79(25):2382-6. PubMed ID: 16920157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of short-term sulodexide treatment on peripheral vascular disease clinical manifestations.
    Caramelli L; Mirchioni R; Carini A
    Riv Eur Sci Med Farmacol; 1988 Feb; 10(1):55-8. PubMed ID: 3079198
    [No Abstract]   [Full Text] [Related]  

  • 14. The effectiveness of glycosaminoglycans in peripheral vascular disease therapy: a clinical and experimental trial.
    Corsi C; Bocci L; Cipriani C; Gazzini A; Marrapodi E
    J Int Med Res; 1985; 13(1):40-7. PubMed ID: 3884410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemorheological and hemodynamic parameters in patients with essential hypertension and their modification by alpha-1 inhibitor drug treatment.
    Toth K; Kesmarky G; Vekasi J; Nemes J; Czopf L; Kapronczay P; Halmosi R; Papp E; Juricskay I
    Clin Hemorheol Microcirc; 1999; 21(3-4):209-16. PubMed ID: 10711745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Flunarizine in the treatment of arteriopathies of the legs].
    Catalano M; Sacchi E; Tomasini M; Coazzoli E; Parolini A; Dall'Oglio A; Libretti A
    Ric Clin Lab; 1985; 15 Suppl 1():475-8. PubMed ID: 4035228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemorheology and tissue oxygenation in hypertensives with lipoidoproteinosis and peripheral occlusive arterial disease (POAD) treated with sulodexide and pravastatine and evaluated with laser assisted optical rotational red cell analyzer (LORCA) and transcutaneous oxymetry.
    Cicco G; Stingi GD; Vicenti P; Tarallo MS; Pirrelli A
    Minerva Cardioangiol; 1999 Oct; 47(10):351-9. PubMed ID: 10670256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do hemorheological alterations play any role in the development of thrombotic events in Behçet's disease?
    Vayá A; Ricart J; Todolí J; Micó L; Contreras T; Aznar J
    Clin Hemorheol Microcirc; 2004; 30(3-4):411-4. PubMed ID: 15258375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use.
    Crepaldi G; Fellin R; Calabrò A; Rossi A; Ventura A; Mannarino E; Senin U; Ciuffetti G; Descovich GC; Gaddi A
    Atherosclerosis; 1990 Apr; 81(3):233-43. PubMed ID: 2190565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemorheological parameters in children with iron-deficiency anemia and the alterations in these parameters in response to iron replacement.
    Halis H; Bor-Kucukatay M; Akin M; Kucukatay V; Bozbay I; Polat A
    Pediatr Hematol Oncol; 2009; 26(3):108-18. PubMed ID: 19382032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.